Respivant Sciences

Respivant Sciences is a clinical-stage biopharmaceutical company that aims to help patients suffering from respiratory diseases. Its lead candidate, RVT-1601, is an inhaled therapeutic delivered directly to the lungs via a proprietary electronic nebulizer device, the PARI eFlow.